Ferring's C. difficile drug overcomes skepticism to secure FDA committee nod
23 Sep 2022
CollaborateVaccine
Preview
Source: FierceBiotech
Ferring has another therapy for Clostridioides difficile, which is in phase 3 trials and is an oral formulation of the rectally delivered RBX7455.
Ferring Pharmaceuticals’ biotherapeutic passed an FDA committee vote despite some skepticism from a handful of members, setting up the asset for potential approval to treat Clostridioides difficile infection.
The FDA’s Vaccines and Related Biological Products Advisory Committee voted 13 to 4 that Ferring's data demonstrated RBX2660 is effective at reducing the recurrence of C. difficile after antibiotic treatment.
The data reviewed by the committee spanned six studies with a total of 1,061 participants, of which 978 were treated with the rectally administered RBX2660, Ferring said in a Sept. 22 release. RBX2660 is a microbiota-based live biotherapeutic designed to deliver a broad range of microbes to the gut to reduce C. difficile infection.
Not every member of the committee was convinced by the data, however. Jay Portnoy, M.D., said the drug had “statistically just squeaked by” and appeared to show “very moderate beneficial effect.”
“Every doctor is going to feel obligated to prescribe it, every patient is going to demand it, and yet only one out of eight patients are going to benefit from it,” Portnoy, who voted against approval, said during the meeting.
Switzerland-based Ferring unveiled data from its most recent phase 3, dubbed PUNCH, in May 2021. The results showed superiority of RBX2660 at reducing recurrence of C. difficile infection over placebo. Specifically, the therapy saw 70.4% of patients free of the infection at eight weeks after treatment, compared to 58.1% in the placebo cohort. The drug also had a comparable safety profile, Ferring noted at the time.
“Patients with recurrent C. difficile infection currently have limited treatment options,” said Paul Feuerstadt, M.D., of Yale University School of Medicine, in the release. “The committee’s vote is a step toward potentially addressing the debilitating cycle of recurrence and the suffering faced by these patients,” added Feuerstadt, who led Ferring’s last phase 3 trial.
C. difficile causes an estimated half a million illnesses and tens of thousands of deaths each year in the U.S. alone, according to the U.S. Centers for Disease Control and Prevention, which classes the the infection a major public health threat.
Ferring has another therapy in phase 3 trials for C. difficile in the form of the oral drug RBX7455. The company is also awaiting an FDA decision on its bladder cancer drug nadofaragene firadenovec.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.